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summary
The aim of this study was to determine the prevalence of T helper 9 (Th9) lymphocytes in rheumatoid arthri-
tis (RA) patients and to identify a possible association between the percentage of Th9 and the discontinuation 
of a biological treatment with an anti-tumor necrosis factor (TNF) (infliximab). 
We collected peripheral blood mononuclear cells (PBMCs) from 55 consecutive RA outpatients and 10 
healthy controls. Among RA patients, 15 were not receiving any immunosuppressive drug, 20 were suc-
cessfully treated with infliximab and 20 discontinued infliximab because of adverse events or inefficacy and 
were treated with other biological agents. PBMCs were cultured with/without infliximab 50 mg/L for 18 h, 
and the percentage of Th9 cells was assessed by means of flow cytometry. Th9 lymphocytes were identified 
as interferon gamma, interleukin (IL)4-, IL17-, IL9-secreting cluster of differentiation 4 (CD4)+ T cells. 
Cytometric analysis revealed no significant decrease in the percentage of Th9 cells after infliximab exposure 
in any of the groups, although it was lower in healthy controls than RA patients either before and after the 
infliximab stimulation assay. 
Th9 cells are IL-9-secreting T helper lymphocytes whose role in RA is still poorly known. IL-9 levels are in-
creased in RA patients, in whom this cytokine plays a crucial role. Th9 cells are the major producers of IL-9, 
and their prevalence is higher in RA patients than in healthy subjects; however our experiment in vitro does 
not demonstrate an association between Th9 lymphocytes and the response to infliximab. Further studies 
are required to evaluate the real involvement of Th9 population in the immunogenicity of anti-TNF agents. 
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n	 INTRODUCTION
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting up to 
1% of worldwide population with a pro-
gressively disabling course. RA is charac-
terized by chronic synovitis of peripheral 
joints, mainly ruled by the uncontrolled ac-
tivation of cells belonging to the adaptive 
immunity. 
Cluster of differentiation 4 (CD4)+ T lym-
phocytes play a central role in the induc-
tion and in the maintenance of the disease, 
due to their complex interplay with den-
dritic cells, macrophages, and B-lympho-
cytes. According to the cytokine milieu, 
CD4+ T lymphocytes may differentiate 
into distinct phenotypes, each of which 
plays a precise role in inducing, tuning 
and repressing the immune response. Over 
the past twenty years, new acquisitions in 
the immunologic field led to the definition 
of five distinct T helper (Th) cell popula-
tions: Th1 cells mainly secreting inter-
feron gamma (IFNγ-), Th2 cells mainly 
secreting interleukin (IL)-4, Th17 cells 
secreting IL-17 and involved in autoim-
mune diseases, Th22 cells secreting IL-22 
and Th9 cells secreting IL-9 (1). A coun-
terpart of T cells with repressive proper-
ties, named T regulatory cells (Tregs), 
was also described. In RA, T helper lym-
phocytes mostly give rise to Th2 or Th17 
responses (2). Th9 are a novel pool of T 
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helper lymphocytes, almost implied in al-
lergic diseases. There is little knowledge 
about the role of Th9 in RA. Indeed, IL-9 
is increased in serum and synovial fluid of 
RA patients. A recent study demonstrated 
that Th9 cells are responsible for the de-
gree of lymphoid organisation in the syno-
vial membrane of RA patients, being also 
related to the titre of anti-cyclic peptide 
antibodies (ACPAs) (3). However, due to 
their peculiar property of orchestrating 
both Th17 and Tregs responses, Th9 cells 
own a more complex function in the im-
munological network at the basis of RA. 
Furthermore, no study has still attempted 
to clarify the implication of these cells in 
the response to a biological treatment with 
an anti-tumor necrosis factor (TNF) agent. 
In a previous study on RA patients (4) we 
demonstrated that the stimulation in vitro 
of peripheral blood mononuclear cells 
(PBMCs) with infliximab could induce a 
paradoxical activation of Th1 and Th17 
lymphocytes while repressing T regula-
tory cells in those patients who had failed 
the treatment with infliximab. According-
ly, we hypothesized that Th9 lymphocytes 
may vary in response to infliximab, con-
ditioning the final outcome of the therapy. 
The primary objective of our study was 
therefore to evaluate the prevalence of Th9 
lymphocytes in the peripheral blood of RA 
patients compared with a group of matched 
healthy controls. 
The secondary objective was to detect the 
association between the percentages of Th9 
cells and the clinical response to a TNF-
blocker (infliximab), following a stimula-
tion test in vitro. 
n	 MATERIALS AND METHODS
We enrolled 55 consecutive RA outpatients 
diagnosed according to the American Col-
lege of Rheumatology/European League 
Against Rheumatism (ACR/EULAR) 2010 
criteria (5). Patients were recruited from our 
previous study (4). This cohort included 15 
subjects affected by early arthritis not con-
currently treated with immunosuppressive 
drugs, 20 patients successfully treated with 
infliximab, 20 patients who had swapped to 
biologic drugs other than infliximab due to 
adverse events or inefficacy, and a matched 
control group of 10 healthy subjects. 
Demographic characteristics are resumed 
in Table I. Patients were concomitantly 
treated with prednisone ≤10 mg/day (at 
a stable dose within 4 weeks since blood 
sampling); methotrexate ≤15 mg/week, 
sulfasalazine ≤3 g/day, hydroxychloro-
quine ≤400 mg/day, all provided that were 
administered at stable dose in the 6 weeks 
before the blood sample. In the group of 
non responder, the patients were treated 
with intravenous (i.v.) abatacept 10 mg/
kg every 4 weeks (13 subjects), i.v. tocili-
zumab 8 mg/kg every 4 weeks (5 subjects), 
subcutaneous (s.c.) etanercept 50 mg once 
a week (1 subject), or s.c. certolizumab 
pegol 200 mg every other week (1 subject), 
as second (8 patients), third (8 patients) or 
fourth biologic line (4 patients). Patients 
with concomitant infections, atopic derma-
titis, haematological disorders, treated with 
leflunomide or cyclosporine, or receiving 
vaccinations in the previous 2 months were 
excluded. The study was approved by a lo-
cal Ethical Committee and all the proce-
dures were performed in accordance with 
the Declaration of Helsinki. 
After giving an informed consent, periph-
eral blood from each subject was collected 
into Vacutainer tubes containing EDTA 
(Becton Dickinson; Rutherford, NJ, USA). 
PBMCs were isolated by centrifugation on 
lymphocyte separation medium (Cedar-
lane Laboratories, Burlington, NC, USA). 
The number and viability of PBMCs were 
determined by an automatic cell counter, 
ADAM-MC (Digital-Bio, NanoEnTek 
Inc., Seoul, Korea). PBMC viability was 
typically >98%.
Cell cultures were performed in RPMI 
1640 plus penicillin, streptomycin, l-gluta-
mine and 10% pooled Human AB Serum 
[all from Euroclone, Siziano (PV), Italy]. 
PBMCs, at a concentration of 1×106 cells/
mL were incubated for 18 h with culture 
medium alone or in the presence of 50 μg/
mL infliximab (Remicade, Janssen Biolog-
ics, Leiden, Netherlands), or 50 μg/mL re-
combinant Human IgG Fc (R&D Systems, 
Minneapolis, MN, USA). Pulse-width mod-
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ulation (lectin from Phytolacca americana; 
1 μg/mL; Sigma-Aldrich, St. Louis, MO, 
USA) was used as a positive control to eval-
uate the responsiveness of PBMCs. To fa-
cilitate co-stimulation, 1 μg/mL anti-human 
CD28 (R&D Systems) was added to the cell 
cultures. Brefeldin A (10 μg/mL; Sigma-Al-
drich) was added after the first three hours in 
order to inhibit cytokine secretion.
The percentage of Th9 lymphocytes was de-
termined by flow cytometric analysis. Th9 
lymphocytes were identified as IFNγ-, IL-
4-, IL-17-, IL-9 secreting CD4+ T cells (6). 
A concentration of infliximab of 50 μg/mL 
was chosen after setting a titration test with 
increasing concentrations of the drug and 
on the basis of the infliximab median serum 
concentrations one hour after infusion (peak 
serum concentration: 39.9-219.1 μg/mL) (7).
The following monoclonal antibodies 
(mAbs) were used: CD4 PE-Cy7, IFNγ 
(Beckman Coulter, Milan, Italy), IL17 
PerCP-Cy5.5 (Biolegend, San Diego, CA, 
USA), IL-9 APC and IL-4 PE (R&D Sys-
tems). PBMCs were incubated 15 min-
utes with the mAbs for the detection of 
cell surface antigens and fixed with 1% 
paraformaldehyde (PFA). Then cells were 
permeabilized with Saponin (Sigma) and 
stained with the antibodies for the detec-
tion of intracellular cytokines. Following a 
45-minute incubation in ice, the cells were 
fixed with 1% PFA. 
Lymphocyte population was gated based 
on the basis of forward and side scatter 
properties, and further gated for CD4 ex-
pression; at least 20,000 events were ac-
quired within the CD4 gate. The samples 
were acquired using a Gallios flow cytom-
eter and data were analysed using Kaluza 
software (both Beckman Coulter). 
As data were normally distributed, proce-
dures were based on parametric analyses. 
Comparisons between the different groups 
were performed using unpaired Student’s t 
test for unequal variances with a two tailed 
P value. Significance was set at P<0.05. 
Statistical analysis was performed using 
GraphPad Prism Software (GraphPad Soft-
ware, San Diego, CA, USA).
Table I - Demographic characteristics of the study population. 
Variables Healthy 
controls
Treatment-naïve 
ra patients
ra patients responding 
to IFX
ra patients not 
responding to IFX
No. 10 15 20 20
Mean age±SD, years 43.9±8.3 54.8 ±16.2 61.3±12.2 57.0±12.2
Mean disease duration±SD, years / 2.3±3.9 13.4±7.2 18.1±9.5
F/M 4/6 12/3 16/4 15/5
ACPA+ / 5 15 15
RF+ / 7 11 15
ANA+ / 2 12 17
Anti-dsDNA Ab+ / 0 3 2
Anti-ENA Ab+ / 0 1 3
ACLA/LAC+ / 0 1 2
Prednisone
(2.5-10 mg/day)
/ / 8 14
Methotrexate
(5-15 mg/week)
/ / 20 9
Hydroxychloroquine 
(200-400 mg/day)
/ / 3 5
NSAIDs / 14 As needed As needed
RA, rheumatoid arthritis; IFX, infliximab; SD, standard deviation; F, females; M, males; ACPA, anti-citrullinated-protein antibodies; RF, 
rheumatoid factor; ANA, anti-nuclear antibodies; anti-dsDNA, anti-double stranded DNA antibodies; anti-ENA, anti-extractable nu-
clear antigen antibodies; ACLA, anticardiolipin antibodies; LAC, lupus anticoagulant; NSAIDs, non-steroidal anti-inflammatory drugs. 
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n	 RESULTS
Our cohort included 20 consecutive RA 
patients (16 females; mean age 61.3±12.2 
years; mean disease duration 13.4±7.2 
years) successfully treated with infliximab 
3 mg/kg every eight weeks, and 20 con-
secutive RA patients (15 females; mean 
age 57.0±12.2 years; mean disease dura-
tion 18.1±9.5 years) who discontinued 
infliximab due to inefficacy (11 cases) or 
adverse events (9 cases). Fifteen patients 
in both the two groups were positive for 
ACPAs, and respectively 11 responders 
and 15 non-responders were positive for 
rheumatoid factor (RF). During inflix-
imab treatment, we detected anti-nuclear 
antibodies (ANAs) in 12 responders and 
17 non-responders without any clinical in-
volvement (Table I). The patients in both 
treated groups concomitantly received the 
allowed disease-modifying antirheumatic 
drugs and corticosteroids.
Cytometric analysis revealed no signifi-
cant decrease in the percentage of Th9 
cells after infliximab exposure in any of 
the groups, but percentage of Th9 cells was 
lower in healthy controls than RA patients 
both before and after the stimulation assay 
with infliximab (Figure 1). 
The higher frequency of Th9 cells in the 
patients was not associated with higher lev-
els of anti-nucleus auto-antibodies or other 
auto-antibody subsets, or with a higher 
likelihood of experiencing an adverse event 
or lack of efficacy on infliximab treatment. 
n	 DISCUSSION
In our work we aimed firstly to evaluate the 
percentage of Th9 lymphocytes in periph-
eral blood of RA patients. Secondly, we 
performed an immune-stimulation assay in 
vitro in order to detect a possible relation-
ship between Th9 cells and the outcome of 
a biologic therapy (infliximab). Th9 cell, 
discovered in 2008 by Veldhoen and col-
leagues, are a T helper cell subset develop-
ing from primary naïve T helper lympho-
cytes or from primed T helper 2 lympho-
cytes in presence of IL-4, TGFb, OX40 
and PU-1 (8). The main cytokine secreted 
is IL-9, but, in vitro, these cells may also 
produce IL-10, IL-17, IL-21 and IL-22 (9). 
It has been demonstrated that Th2 cells, 
Th17 cells, Treg cells, innate lymphoid 
cells, mast cells, natural killer cells are 
capable of releasing large amount of IL-9 
(10). However, Th9 cells are a distinct class 
of CD4+ T lymphocytes, identified by a pe-
culiar set of transcriptional factors (PU.1, 
IRF-4). The role played by Th9 cells has 
been investigated in vivo and in vitro. Th9 
lymphocytes seem to be involved in the 
immunological responses underlying para-
sitic infections as well as allergic diseases 
(11, 12). A consistent number of reports 
has evidenced that these cells are highly 
represented in the airways of asthmatic 
subjects as well as in the skin of people 
suffering from atopic dermatitis (13, 14). 
Recent reports on melanoma tumor mod-
els have evidenced that Th9 lymphocytes 
enhance the intra-tumor expression of che-
mokines and their receptors such as CCL20 
and CCR6, thus promoting the recruitment 
of dendritic cells and anti-tumor CD8+ T 
lymphocytes (15). 
The role of Th9 cells in rheumatic diseases 
is less characterized. According to some 
Figure 1 - The percentage of gamma interferon (IFNγ)-, interleu-
kin (IL)4-, IL17-, IL9-secreting CD4+ T cells in rheumatoid arthri-
tis patients and healthy controls under unstimulated and infliximab 
(IFX)-stimulated conditions. Mean values ± standard error. *P<0.05; 
**P<0.01 (Student’s t test).
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studies, IL-9 may contemporarily favor the 
differentiation of Th17, acting like IL-6 or 
IL-21 in the presence of TGFb, and inhibit 
the apoptosis of Treg cells, by enhancing 
the expression of STAT5. Mice knock-out 
for IL-9R gene develop a more aggressive 
form of experimental autoimmune enceph-
alomyelitis when compared to wild types, 
mainly due to an over-expansion of Th1 
lineage (16). Similar results were obtained 
in a recent report that analysed the cytokine 
interplay in human skin samples and mu-
rine models of atopic dermatitis, finding 
an indirect regulation of IL-9 on IFNγ ex-
pression (17). On the other hand IL-23 and 
IL-21 represent inhibiting cytokines for the 
development of Th9 lineage. IL-9 mRNA 
and IL-9R have been found significantly 
increased in gut specimens from ulcer-
ative colitis patients, where this cytokine 
may activate neutrophils and epithelial 
cells, delaying ulcers healing (18). In the 
gut, Th9 cells are involved in the defence 
against parasitic infections and an increase 
in this T helper subset may represent a link 
between dysbiosis and autoimmune in-
flammatory bowel diseases (11). One study 
on connective tissue diseases reported that 
IL-9 serum levels were increased in sys-
temic sclerosis but not in systemic lupus 
erythematosus or dermatomyositis, being 
inversely correlated with the degree of lung 
fibrosis (19). This result may be interpreted 
in the light of the pleiotropic effects of IL-
9, promoting at the same time the expan-
sion of Treg and Th17 lymphocytes (Figure 
2) (20).
To our knowledge, there are actually few 
studies on the involvement of IL-9 in RA. 
One study analysed by multiple suspension 
array the serum cytokine profile of 6 RA pa-
tients undergoing rituximab treatment after 
failing a previous therapy line with inflix-
imab. The authors found increased levels of 
IL-9 at baseline and at follow-up times in 
responder patients and concluded that IL-9 
may be considered as a predictive marker 
of response to rituximab (21). Another 
Figure 2 - The network of interleukin (IL)-9 and IL-9 producing cells. Th9 lymphocytes are induced following the stimu-
lation with IL-4, TGFb, IL-1, IL-2 and the interaction of TCR, OX40 and CD28 with their ligandos; on the contrary, IFNγ, 
IL-21 and IL-23 inhibit their differentiation. Th9 cells express specific transcriptional factors (PU.1 and IRF-4) that favor 
the activation of NFkB. Beyond Th9 lymphocytes, Th17 cells, T regulatory cells, eosinophils, mast cells, innate lymphoid 
cells (ILCs) and polymorphonucleates (PMN) may produce IL-9. IL-9 interacts with its receptor (IL-9R), composed by a 
specific a- and a common γ chain, thus activating an intracellular pathway that promotes the transcription of specific 
genes involved in survival of either Th17 (implied in autoimmunity) and T regulatory cells (implied in immune-tolerance). 
No
n-c
om
me
rci
al 
us
 on
ly
original
paper
88 Reumatismo 2/2016
 
R. Talotta, A. Berzi, F. Atzeni, et al.
study on 44 subjects showed an increased 
serum concentration of IL-9 in first-degree 
relatives of RA patients, which was asso-
ciated to a higher ratio of auto-antibodies 
positivity, such as RF or ACPAs (22). A re-
cent report on RA, psoriatic arthritis (PsA) 
and osteoarthritis (OA) patients showed an 
augmented concentration of IL-9 in blood 
and synovial fluid of RA and PsA subjects 
than in OA ones. Furthermore the treatment 
of magnetically sorted synovial and blood 
CD3+ T cells with recombinant IL-9 in-
duced their expansion only in RA and PsA 
samples, underlining the hyper-expression 
of IL-9R on cells coming from patients suf-
fering from autoimmune arthritis (23). Fi-
nally, a recent histological study on syno-
vial membrane biopsies from RA patients 
evidenced an augmented expression of Th9 
lymphocytes in the most aggressive forms 
of disease and an association between these 
cells and the organisation of the lymphoid 
centres or the synthesis of ACPAs (3). In 
line with these data, our results showed an 
increased percentage of Th9 cells in the pe-
ripheral blood of RA patients when com-
pared to healthy controls, but no difference 
was noticed before and after the incubation 
of PBMCs in vitro with infliximab. A limit 
of the study was that we did not sorted Th9 
lymphocytes according to the specific tran-
scriptional factor profile (PU.1 or IRF-4), 
perhaps including other T CD4+ subsets in 
the pool of Th9 producing cells. 
However, these data may also reflect the 
bipolar effects of these cells, favoring at 
the same time the survival and the activa-
tion of Th17 and Treg lymphocytes. Due to 
their ambivalent behavior, Th9 cells would 
be therefore not suitable for predicting the 
response or the failure to a specific treat-
ment in RA patients. Figure 2 resumes the 
complexity of the role of Th9 cells played 
in the immune network. 
n	 CONCLUSIONS
In conclusion, IL-9 levels are increased in 
RA patients. Th9 cells are the major pro-
ducers of IL-9, and their amount is higher 
in RA patients than in healthy subjects; 
however our experiment in vitro does not 
demonstrate an association between Th9 
lymphocytes and the response to inflix-
imab. IL-9 producing cells restore a bal-
ance between tolerance and inflammation 
and, according to our results, cannot be 
considered a reliable marker in predicting 
the response to anti-TNF agents. However 
our study has some limits and the actual 
knowledge about the biologic effects of 
these cells in RA is still incomplete and re-
quires further investigations. 
Conflict of interest: the authors declare no 
potential conflict of interest.
Acknowledgements: we acknowledge all 
of the physicians in the Rheumatology Unit 
of Luigi Sacco University Hospital for giv-
ing us access to the patients’ source docu-
ments. 
Conference presentation: LII SIR Con-
gress, 2015.
n	 REFERENCES
1. Li P, Spolski R, Liao W, Leonard WJ. Com-
plex interaction of transcription factors in 
mediating cytokine biology in T cells. Immun 
Rev. 2014; 261: 141-56. 
2. Alunno A, Manetti M, Caterbi S, et al. Altered 
immunoregulation in rheumatoid arthritis: the 
role of regulatory T cells and proinflammatory 
Th17 cells and therapeutic implications. Me-
diators Inflamm. 2015; 2015: 751-93.
3. Ciccia F, Guggino G, Rizzo A, et al. Poten-
tial involvement of IL-9 and Th9 cells in the 
pathogenesis of rheumatoid arthritis. Rheuma-
tology (Oxford). 2015; 54: 2264-72.
4. Talotta R, Berzi A, Atzeni F, et al. Paradoxi-
cal expansion of Th1 and Th17 lymphocytes 
in rheumatoid arthritis following infliximab 
treatment: a possible explanation for a lack of 
clinical response. J Clin Immunol. 2015; 35: 
550-7.
5. Aletaha D, Neogi T, Silman AJ, et al. 2010 
Rheumatoid arthritis classification criteria: 
an American College of Rheumatology/Eu-
ropean League Against Rheumatism collab-
orative initiative. Arthritis Rheum. 2010; 62: 
2569-81. 
6. Schlapbach C, Gehad A, Yang C, et al. Human 
TH9 cells are skin-tropic and have autocrine 
and paracrine proinflammatory capacity. Sci 
Transl Med. 2014; 6: 219ra8.
7. Clair EW, Wagner CL, Fasanmade AA, et al. 
The relationship of serum infliximab concen-
No
n-c
om
me
rci
l u
se
 on
ly
Reumatismo 2/2016 89
original
paperEvaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients
trations to clinical improvement in rheumatoid 
arthritis: results from ATTRACT, a multi-
center, randomized, double-blind, placebo-
controlled trial. Arthritis Rheum. 2002; 46: 
1451-9.
8. Zhao P, Xiao X, Ghobrial RM, Li XC. IL-9 
and Th9 cells: progress and challenges. Int Im-
munol. 2013; 25: 547-51.
9. Dardalhon V, Awasthi A, Kwon H, et al. IL-4 
inhibits TGF-b-induced Foxp3+ T cells and, 
together with TGF-b, generates IL-9+ IL-10+ 
Foxp3(-) effector T cells. Nat Immunol. 2008; 
9: 1347-55.
10. Schmitt E, Klein M, Bopp T. Th9 cells, new 
players in adaptive immunity. Trends Immu-
nol. 2014; 35: 61-8.
11. Licona-Limón P, Henao-Mejia J, Temann AU, 
et al. Th9 cells drive host immunity against 
gastrointestinal worm infection. Immunity. 
2013; 39: 744-57. 
12. Kaplan MH. Th9 cells: differentiation and dis-
ease. Immunol Rev. 2013; 252: 104-15.
13. Übel C, Graser A, Koch S, et al. Role of Tyk-2 
in Th9 and Th17 cells in allergic asthma. Sci 
Rep. 2014; 4: 58-65.
14. Ma L, Xue HB, Guan XH, et al. Possible 
pathogenic role of T helper type 9 cells and in-
terleukin (IL)-9 in atopic dermatitis. Clin Exp 
Immunol. 2013; 175: 25-31.
15. Lu Y, Yi Q. Utilizing Th9 cells as a novel ther-
apeutic strategy for malignancies. Oncoimmu-
nology. 2013; 2: e23084.
16. Elyaman W, Bradshaw E, Uyttenhove C, et al. 
IL-9 induces differentiation of Th17 cells and 
enhances function of FoxP3+ natural regula-
tory T cells. PNAS. 2009; 106: 12885-90.
17. Liu J, Harberts E, Tammaro A, et al. IL-9 
regulates allergen-specific Th1 responses in 
allergic contact dermatitis. J Invest Dermatol. 
2014; 134: 1903-11.
18. Nalleweg N, Chiriac MT, Podstawa E, et al. IL-9 
and its receptor are predominantly involved in 
the pathogenesis of UC. Gut. 2015; 64: 743-55.
19. Yanaba K, Yoshizaki A, Asano Y, et al. Serum 
interleukin-9 levels are increased in patients 
with systemic sclerosis: association with low-
er frequency and severity of pulmonary fibro-
sis. J Rheumatol. 2011; 38: 2193-7.
20. Leng RX, Pan HF, Ye DQ, Xu Y. Potential role 
of IL-9 in the pathogenesis of systemic lu-
pus erythematosus. Am J Clin Exp Immunol. 
2012; 1: 28-32. 
21. Khan IH, Krishnan VV, Ziman M, et al. Com-
parison of multiplex suspension array large-
panel kits for profiling cytokines and chemo-
kines in rheumatoid arthritis patients. Clin 
Cytometry. 2009; 76B: 159-68.
22. Hughes-Austin JM, Deane KD, Derber LA, 
et al. Multiple cytokines and chemokines are 
associated with rheumatoid arthritis-related 
autoimmunity in first-degree relatives without 
rheumatoid arthritis: Studies of the Aetiology 
of Rheumatoid Arthritis (SERA). Ann Rheum 
Dis. 2013; 72: 901-7.
23. Raychaudhuri S, Mitra A, Mitra AD, et al. Th9 
cells in inflammatory cascades of autoimmune 
arthritis. Arthritis Rheum. ACR abstracts. 
2014; 66: S708.
No
n-c
om
me
rci
al 
se
 on
ly
